Clinical Cardiology Alert – October 1, 2018
October 1, 2018
View Issues
-
Who Really Needs Intensive Blood Pressure Control?
A patient baseline characteristics level analysis of the SPRINT and ACCORD trials resulted in the creation of a simple algorithm for identifying high-risk patients who experienced fewer major cardiac events without increased serious adverse events from intensive blood pressure therapy.
-
MitraClip Falls Short in First Randomized Trial Specific to Functional Mitral Regurgitation
The authors of a recent study concluded that percutaneous mitral valve repair with MitraClip did not significantly alter rates of death and heart failure hospitalization at one year over medical therapy alone.
-
Tafamidis Improves Survival in Transthyretin Cardiac Amyloidosis
Treatment with tafamidis in transthyretin amyloid cardiomyopathy patients produced reductions in all-cause mortality and cardiovascular hospitalizations. This was the first medical therapy to demonstrate improved survival for patients with this condition.
-
Clinical Context and Outcomes in Stress Cardiomyopathy
An analysis of the International Takotsubo Registry showed that long-term mortality is similar to that observed in patients with acute coronary syndromes but varies widely depending on the triggering event.
-
MRI for Patients With Pacemakers and Defibrillators
Performing an MRI on patients with pacemakers and defibrillators that were not MRI-conditional was not associated with any clinically significant changes in device parameters.